Lembas is a new b2b ingredient business that makes a peptide powder that targets the GLP-1 hormone for weight loss ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Omada Health closed 21% higher in its Nasdaq debut after raising $150 million. Backed by strong growth and GLP-1 momentum, ...

Metsera has linked its amylin analog to 8.4% placebo-adjusted weight loss at Day 36, advancing its push to develop an ...

A bipartisan bill soon to be introduced in the state Legislature seeks to decrease the cost of GLP-1 drugs in Pennsylvania.

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Novo Nordisk and Eli Lilly are ... obesity drugs or expecting obesity drug pricing to remain stable. To support their current valuations, US GLP-1 market penetration into obesity would need ...